West Pharmaceutical Services, Inc. (NYSE:WST) Stock Position Trimmed by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC decreased its position in West Pharmaceutical Services, Inc. (NYSE:WST) by 3.0% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 2,030 shares of the medical instruments supplier’s stock after selling 63 shares during the period. Mount Yale Investment Advisors LLC’s holdings in West Pharmaceutical Services were worth $669,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in WST. Pitcairn Co. grew its holdings in West Pharmaceutical Services by 3.4% in the 1st quarter. Pitcairn Co. now owns 875 shares of the medical instruments supplier’s stock worth $346,000 after buying an additional 29 shares in the last quarter. Copperwynd Financial LLC grew its stake in shares of West Pharmaceutical Services by 4.0% in the fourth quarter. Copperwynd Financial LLC now owns 778 shares of the medical instruments supplier’s stock worth $274,000 after purchasing an additional 30 shares in the last quarter. Clearbridge Investments LLC increased its holdings in shares of West Pharmaceutical Services by 0.7% during the first quarter. Clearbridge Investments LLC now owns 4,495 shares of the medical instruments supplier’s stock valued at $1,779,000 after purchasing an additional 31 shares during the period. RFG Advisory LLC increased its holdings in shares of West Pharmaceutical Services by 2.3% during the first quarter. RFG Advisory LLC now owns 1,465 shares of the medical instruments supplier’s stock valued at $580,000 after purchasing an additional 33 shares during the period. Finally, Ballentine Partners LLC raised its stake in shares of West Pharmaceutical Services by 4.7% during the second quarter. Ballentine Partners LLC now owns 742 shares of the medical instruments supplier’s stock valued at $244,000 after purchasing an additional 33 shares in the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

West Pharmaceutical Services Stock Performance

Shares of WST opened at $306.73 on Tuesday. The firm has a market capitalization of $22.34 billion, a PE ratio of 40.47, a P/E/G ratio of 10.58 and a beta of 1.01. The company has a quick ratio of 1.68, a current ratio of 2.34 and a debt-to-equity ratio of 0.03. The firm has a 50-day moving average price of $303.10 and a 200 day moving average price of $336.80. West Pharmaceutical Services, Inc. has a 52-week low of $265.00 and a 52-week high of $413.70.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings data on Thursday, July 25th. The medical instruments supplier reported $1.52 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The company had revenue of $702.10 million during the quarter, compared to the consensus estimate of $729.36 million. During the same quarter last year, the business earned $2.11 earnings per share. The company’s revenue was down 6.9% on a year-over-year basis. On average, sell-side analysts anticipate that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current fiscal year.

Insider Activity

In other news, VP Charles Witherspoon sold 1,029 shares of the company’s stock in a transaction on Monday, August 19th. The stock was sold at an average price of $300.00, for a total value of $308,700.00. Following the completion of the sale, the vice president now owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a legal filing with the SEC, which is available at this link. 0.53% of the stock is owned by insiders.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.